SCHEMBL4227234

SCHEMBL4227234

NC(=O)CC[C@H](NC(=O)[C@@H](N)CS)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.48
ALOX15 P16050 1/20 0.48
BLM P54132 1/20 0.48
PMP22 Q01453 1/20 0.48
FOLH1 Q04609 2/20 0.47
FNTA P49354 4/20 0.46
FNTB P49356 4/20 0.46
PGGT1B P53609 3/20 0.46
DPP4 P27487 1/20 0.44
DPP8 Q6V1X1 1/20 0.44
DPP9 Q86TI2 1/20 0.44
PTGS1 P23219 2/20 0.44
NOD1 Q9Y239 1/20 0.44
SLC7A11 Q9UPY5 1/20 0.44
CA2 P00918 4/20 0.43
CA1 P00915 3/20 0.43
ACE P12821 1/20 0.42
RIMKLA Q8IXN7 1/20 0.42
NAALAD2 Q9Y3Q0 1/20 0.42
GSTK1 Q9Y2Q3 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4227222 1.00 KMT2A (0.48) KMT2AALOX15BLMPMP22FOLH1
SCHEMBL7071336 0.95 FOLH1 (0.47) KMT2AALOX15BLMPMP22FOLH1
SCHEMBL7071333 0.95 FOLH1 (0.47) KMT2AALOX15BLMPMP22FOLH1
SCHEMBL30011195 0.92 FOLH1 (0.47) KMT2AALOX15BLMPMP22FOLH1
SCHEMBL30010559 0.92 FOLH1 (0.47) KMT2AALOX15BLMPMP22FOLH1
SCHEMBL30010906 0.92 FOLH1 (0.47) KMT2AALOX15BLMPMP22FOLH1
SCHEMBL30010917 0.92 FOLH1 (0.47) KMT2AALOX15BLMPMP22FOLH1
SCHEMBL29615273 0.91 DPP4 (0.44) KMT2AALOX15BLMPMP22FOLH1
SCHEMBL29615137 0.91 DPP4 (0.44) KMT2AALOX15BLMPMP22FOLH1
SCHEMBL6809858 0.89 KMT2A (0.49) KMT2AALOX15BLMPMP22FOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103623390-A Glutamine for use in treating injury UNIV COLORADO 2014-03-12 CN claimed
EP-1663283-B1 GLUTAMINE FOR USE IN TREATING INJURY UNIV COLORADO (US) 2012-05-23 EP claimed
EP-2106791-A1 Glutamine or glutamine-containing dipeptide in a specific dosage for the treatment of inflammation Biotempt B.V. (NL) 2009-10-07 EP claimed
EP-1663283-A4 GLUTAMINE FOR USE IN TREATING INJURY UNIV COLORADO (US) 2008-08-20 EP claimed
CN-1878564-A Glutamine for the treatment of injury UNIV COLORADO (US) 2006-12-13 CN claimed
EP-1663283-A1 GLUTAMINE FOR USE IN TREATING INJURY University of Colorado (US) 2006-06-07 EP claimed
WO-2005034980-A1 GLUTAMINE FOR USE IN TREATING INJURY UNIVERSITY OF COLORADO (US) 2005-04-21 WO claimed
US-20050059610-A1 Glutamine for use in treating injury REGENTS OF THE UNIVERSITY OF COLORADO, THE 2005-03-17 US claimed
EP-4684030-A2 METHOD OF DEPROTECTING AT LEAST ONE D-AMINO ACID AND/OR D-AMINO ACID DERIVATIVE PROTECTED FUNCTIONAL GROUP Martin-Luther-Universität Halle-Wittenberg (DE) 2026-01-28 EP disclosed
US-20250074942-A1 COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E CALICO LIFE SCIENCES LLC (US) 2025-03-06 US disclosed
WO-2024227957-A2 METHOD OF DEPROTECTING AT LEAST ONE D-AMINO ACID AND/OR D-AMINO ACID DERIVATIVE PROTECTED FUNCTIONAL GROUP Martin-Luther-Universität Halle-Wittenberg (DE) 2024-11-07 WO disclosed
US-20240173375-A1 CHEMOTACTIC AUTOPHAGY-INHIBITING PEPTIDE, COMPOSITIONS AND METHODS RELATED THERETO BIOTEMPT B.V. (NL) 2024-05-30 US disclosed
EP-4301391-A1 CHEMOTACTIC AUTOPHAGY-INHIBITING PEPTIDE, COMPOSITIONS AND METHODS RELATED THERETO Biotempt B.V. (NL) 2024-01-10 EP disclosed
US-20230173089-A1 Q-ER PEPTIDE BIOTEMPT B.V. (NL) 2023-06-08 US disclosed
EP-1663283-A1 GLUTAMINE FOR USE IN TREATING INJURY University of Colorado (US) 2006-06-07 EP disclosed
WO-2005034980-A1 GLUTAMINE FOR USE IN TREATING INJURY UNIVERSITY OF COLORADO (US) 2005-04-21 WO disclosed
US-20050059610-A1 Glutamine for use in treating injury REGENTS OF THE UNIVERSITY OF COLORADO, THE 2005-03-17 US disclosed
EP-0571198-B1 Cosmetic composition containing hair-growth promoter UNILEVER PLC (GB) 1997-03-19 EP disclosed
US-5559092-A HAIR GROWTH, GLUTAMINE DIPEPTIDE CHESEBROUGH-POND'S USA CO. DIVISION OF CONOPCO, INC. (US) 1996-09-24 US disclosed
EP-0571198-A1 Cosmetic composition containing hair-growth promoter UNILEVER PLC (GB) 1993-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074942-A1 COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E MICA, CD74, HLA-DRB1 KMT2A 357/4885ALOX15 3715/4885BLM 3938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.